The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Introduction:

The onychomycosis market has witnessed robust growth in recent years, driven by factors such as limited treatment options, an aging population, and the increased incidence of diabetes. This growth trend is expected to continue, with innovations in treatment modalities and expanding healthcare infrastructure contributing to market expansion.

Rising Diabetic Population Fuels Market Growth:

• The surge in diabetes cases globally is a significant driver for the onychomycosis market.
• Onychomycosis, a common foot problem for people with diabetes, amplifies the demand for effective treatments.
• Statistics from the International Diabetes Federation underscore the growing prevalence of diabetes, further propelling market growth.

Innovation in Onychomycosis Treatment by Bausch Health Companies Inc.:

• Product innovation plays a pivotal role in sustaining market competitiveness.
• Bausch Health Companies Inc. introduced Julia (aliconazole) topical solution, approved by the American Podiatric Medical Association, enhancing treatment options for onychomycosis.

View More On The Onychomycosis Market Report 2024 – https://www.thebusinessresearchcompany.com/report/onychomycosis-global-market-report

Kaken Pharmaceutical Boosts R&D Capabilities with Acquisition of Artha Therapeutics:

• Strategic acquisitions bolster research and development efforts within the industry.
• Kaken Pharmaceutical’s acquisition of Artha Therapeutics enhances its R&D capabilities, particularly in drug repositioning and topical treatments for onychomycosis.

Segmentation of the Onychomycosis Market: The onychomycosis market is segmented based on:

1. Type: Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), and others.
2. Treatment: Drug Treatment, Topical Therapy, and Other Treatments.
3. Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, and Other Distribution Channels.

Regional Insights:

• North America dominated the onychomycosis market in 2023, driven by advanced healthcare infrastructure and high disease prevalence.
• Asia-Pacific is poised to exhibit the fastest growth, attributed to improving healthcare access and rising awareness of fungal infections.

Future Outlook and Trends:

• The onychomycosis market is forecasted to reach $4.45 billion by 2028.
• Major trends in the forecast period include the integration of digital technologies in diagnosis and management, the rise of over-the-counter antifungal products, and personalized treatment approaches.
• Collaborations between pharmaceutical companies for R&D purposes will continue to drive innovation in the market.

Conclusion: The onychomycosis market demonstrates significant growth potential, fueled by factors such as the increasing diabetic population and advancements in treatment options. With a focus on innovation and strategic partnerships, the market is poised to address the evolving needs of patients affected by fungal infections, offering hope for improved management and outcomes.

Request A Sample Of The Global Onychomycosis Market Report 2024:

https://www.thebusinessresearchcompany.com/sample_request?id=12197&type=smp